The incretin concept today

Diabetologia

Volumn 16, Issue 2, 1979, Pages 75-85

  Creutzfeldt, W ^a,b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

entero insular axis; gastrointestinal hormones; GIP; Incretin; insulin secretion

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; INSULIN DERIVATIVE;

DIGESTIVE SYSTEM; ENDOCRINE SYSTEM; ETIOLOGY; GASTROINTESTINAL MUCOSA; INCRETIN; REVIEW;

ABSORPTION; DIABETES MELLITUS; FEEDBACK; GASTRINS; GASTROINTESTINAL HORMONES; HUMAN; INSULIN; NEUROTRANSMITTERS; OBESITY; PEPTIDES; VAGUS NERVE;

EID: 0018758893     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/BF01225454     Document Type: Review

References (82)

1. Quantitative relations between the oral and intravenous glucose tolerance curves
2. On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane
3. Contributions à l'étude des variations physiologiques de la sécrétion interne du pancréas: relations entre les sécretions externe et interne du pancréas
4. Studies on the physiology of secretin. III Further studies on the effects of secretin on the blood sugar
5. Über den blutzuckerwirksamen Stoff im Sekretinextrakten
6. Über das insulinotrope Hormon der Darmschleimhaut (Duodenin)
7. New interpretation of oral glucose tolerance
8. Plasma insulin responses to oral and intravenous glucose administration
9. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects
10. Entero-insular axis
11. Chiens rendus diabetique
12. Neural control of the endocrine pancreas
13. Sur l'augmentation de la teneur en insuline du sang veineux pancréatique après excitation du nerf vague
14. Peptidergic nerves in the gut
15. Effects of gastrointestinal hormones — physiological or pharmacological?
16. Innervation of the pancreas by vasoactive intestinal polypeptide (VIP) immunoreactive nerves
17. Effect of intrapancreatic administration of vasoactive intestinal peptide upon the release of insulin and glucagon in dogs
18. Stimulation of insulin und glucagon secretion by vasoactive intestinal peptide
19. Effect of vasoactive intestinal peptide (VIP) and gastric inhibitory peptide (GIP) on insulin and glucagon release by perifused newborn rat pancreas
20. Glucose turnover and insulin secretion in dogs with orthotopic pancreatic allograft
21. The enteral insulin-stimulation after pancreas transplantation in the pig
22. Effect of gastrointestinal hormones on insulin and glucagon secretion
23. Gastrointestinal hormones and insulin secretion
24. Insulin-releasing factors of the gastroinestinal mucosa (incretin)
25. Gastrointestinal hormones and the control of insulin secretion
26. Release of vasoactive intestinal polypeptide (VIP) by intraduodenal stimuli
27. Gastric glucagon and gut glucagon-like immunoreactants
28. The tissue distribution and plasma levels of glicentin (gut GLI-I)
29. The effect of gastrin on basal- and glucose-stimulated insulin secretion in man
30. Effect of secretin on basal- and glucose stimulated insulin secretion in man
31. Stimulation of insulin secretion by gastric inhibitory polypeptide in man
32. Identification and actions of gastric inhibitory polypeptide
33. Insulin and glucagon responses to infusion of gastric inhibitory polypeptide (GIP) in man during controlled glycemia
34. The glucose-induced gastrointestinal stimulation of insulin secretion in man: relation to age and to gastrin release
35. The effect of gastrin on basal and aminoacid-stimulated insulin and glucagon secretion in man
36. Gastric inhibitory polypeptide. Its physiologic release and insulinotropic action in the dog
37. Inhibition of gastric acid secretion by gastric inhibitory polypeptide (GIP) in man
38. Effects of the gastric inhibitory polypeptide present in impure pancreozymin-cholecystokinin on plasma insulin and glucagon in the rat
39. Effects of pancreozymin and secretin on insulin release and the role of the exocrine pancreas
40. Insulin stimulating effect of some caerulein-like peptides in the dog
41. Effect of caerulein upon insulin and glucagon secretion in dog
42. Effect of gastrin and its C-terminal tetrapeptide on insulin secretion in man
43. Selective release of gastric inhibitory polypeptide by intraduodenal amino acid perfusion in man
44. Gastric inhibitory polypeptide: effect on glucose-induced insulin release from isolated rat pancreatic islets in vitro
45. The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas
46. GI hormones and insulin secretion
47. Release of immunoreactive gastric inhibitory polypeptide (IR-GIP) by oral ingestion of food substances
48. Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man
49. Stimulation of secretion of gastric inhibitory polypeptide and insulin by intraduodenal amino acid perfusion
50. Different forms of immunoreactive gastric inhibitory polypeptide (IR-GIP) in human serum and intestinal mucosa
51. The effect of duodenal stimulation in man upon alimentary and adrenaline hyperglycemia
52. Effects of secretin, pancreozymin, or gastrin on the response of the endocrine pancreas to administration of glucose or arginine in man
53. Gastric inhibitory polypeptide (GIP), gastrin and insulin: response to test meal in coeliac disease and after duodenopancreatectomy
54. Aspect of GIP pathology
55. Glucosidase inhibition
56. α-glucosidase inhibitors
57. The insulinotropic effect of endogenous gastric inhibitory polypeptide in normal subjects
58. Oral glucose augmentation of insulin secretion
59. Inhibition of fat, but not glucose induced release of gastric inhibitory polypeptide (GIP) by insulin or glucose
60. Effect of atropine on glucose-stimulated gastric inhibitory polypeptide
61. The effect of atropine on the insulin release caused by oral and intravenous glucose in human subjects
62. Serum gastric inhibitory polypeptide (GIP) in duodenal ulcer disease: relationship to glucose tolerance, insulin and gastrin release
63. Stimulation of gastric inhibitory polypeptide in normal and duodenal ulcer patients
64. The response of gastric inhibitory polypeptide (GIP) and insulin to glucose in duodenal ulcer patients
65. Carbohydrate metabolism in duodenal ulcer patients
66. Glucose tolerance and insulin secretion in patients with chronic duodenal ulcer
67. Gastric inhibitory polypeptide in maturity-onset diabetes mellitus
68. GIP in diabetes
69. Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus
70. Serum gastric inhibitory polypeptide (GIP) response in patients with maturity onset diabetes and in juvenile diabetics
71. Serum gastric inhibitory polypeptide (GIP) levels in obese subjects and after weight reduction
72. Gastric inhibitory polypeptide (GIP) and insulin in obesity: increased response to stimulation and defective feedback control of serum levels
73. Gastric inhibitory polypeptide (GIP) and insulin in obesity: II. Reversal of increased response to stimulation by starvation or food restriction
74. A study of the diabetic syndrome produced in rats by antiinsulin serum
75. Is gastrin a major determinant of basal lower esophageal sphincter pressure?
76. Abolishment of the incretin effect in rats by infusion of gastric inhibitory polypeptide (GIP) antibodies